Search all trials

Find therapies in clinical trials near you – page 7

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 987
countries: 28
conditions: 2 109

3 987 trials recruiting28 European countries2 109 conditions coveredUpdated today

Quick filters

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AZD0901

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Malignant mast cell neoplasm

Recruiting

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Efanesoctocog Alfa

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug